Tetanus is a disease that mainly affects the central and peripheral nervous systems. The clinical features of tetanus and relationship to wounds and injuries are well known dated back to ancient times. Tetanus is synonymous with the term "lockjaw," a cardinal sign as a reminder of the intense, painful spasms of the masseter muscles, and an inability to open the mouth. Tetanus has 4 manifestations, including localized, generalized, cephalic, and neonatal. Localized tetanus often have localized muscle rigidity. Generalized tetanus often presents with trismus, dysphagia, and nuchal rigidity associated with systemic rigidity and tonic contractions. Cephalic tetanus may present with cranial nerve paralysis. Neonatal tetanus presents with an irritable infant and develop severe rigidity.
Tetanus is now rare in developed nations due to effective immunization programs, but it remains a threat to all unvaccinated people, especially in undeveloped nations. Most reported cases in the United States are attributed to unvaccinated individuals, and improper identification and treatment of wounds and traumatic injuries.
Tetanus has high morbidity and mortality worldwide before the development of tetanus toxoid in 1924. The first vaccine was not very effective and had significant adverse effects. A better and safer version became available in 1938. It became widely used in the 1940s during World War II for soldiers, which resulted in a 95% reduction in the rate of tetanus. The tetanus toxoid is considered worldwide as the safest and most effective medicine in healthcare.
Tetanus toxoid is used in combination with Diptheria and pertussis as vaccines. Currently, there is five tetanus toxoid containing vaccines (DTaP, DTP, Tdap, Td, DT). Nomenclature is as followed: D is for diphtheria, T is for tetanus, P is for pertussis, and a is for acellular. The lower case p and d just mean reduced toxoid of that vaccine. DTP (diptheria, tetanus, pertussis) was used from 1948 to 1991. It was discontinued due to a high adverse injection reaction of redness, swelling, and pain around the site. Two new vaccines replaced it in 1992, TDaP and DTaP.
Current Advisory Committee on Immunization Practices (ACIP) recommends for children doses of DTaP or DT at 2, 4, and 6 months of age, with additional doses between 15 and 18 months, and between 4 and 6 years. This regimen is followed by 1 booster of Tdap at age 11 or 12, followed by a booster every ten years thereafter. Adult Td or Tdap vaccine is recommended every 10 years with complete prior immunization. Of those doses, one must be Tdap for more than 19 years old. In those previously unvaccinated, a series of three vaccines will be given. One dose is given four weeks from the first dose, then last dose 6 to 12 months later. At least one dose is Tdap, and the other two can be Td or Tdap. A booster is indicated also every ten years thereafter. The rationale for booster every 10 years is due to waning immunity. Between 1988 and 1994, the United States serologic survey finds protective titers of tetanus antibodies were detected in 72% aged 6 years old, up to 91% aged 6 and 11 years old, down 47% aged 20 years or older, and significantly down to 31% aged more than 70 years old.
Tetanus prophylaxis includes understanding and knowing the current tetanus immunization guideline(s), recommendation(s), and indication(s) for prophylaxis.
The key to the prevention of tetanus is immunization, identification of those at risk, and proper identification and treatment of wounds and traumatic injuries.
Tetanus is a disease caused by Clostridium tetani, a toxin-producing obligate anaerobe, which is found in the soil and gut of mammals. The spores cannot be eliminated from the environment. They may enter the body through compromises in the skin barrier or mucous membranes. Once inoculated, C. tetani transforms into a vegetative bacterium which then travels to the spinal cord and brainstem via the motor neurons. It then produces neurotoxin tetanospasmin which interferes with nervous system inhibitory neurotransmitters. C. tetani also produces tetanolysin which has hemolytic properties and causes membrane damage but its role is unknown.
Since the 1940s, due to universal vaccinations of children in developed nations, the incidence has dropped dramatically and steadily. According to the Center for Disease Control and Prevention, between 2009 to 2017, there were 264 cases reported. 23% of those cases were age more than 65 years old, and 13% were less than 20 years old. Mortality was about 7%, and all deaths were more than 55 years old. The highest risk for both tetanus and death is more than 65 years old. Age plays a significant factor due to waning immunity. Similar data are reported worldwide in developed nations.
Prior to the widespread vaccination with tetanus toxoid in the late 1940s, there were approximately 600 cases of tetanus per year in the United States. Since then, the tetanus vaccine has achieved near-universal coverage in the United States, which has resulted in a 96% reduction in the incidence of tetanus cases and the elimination of neonatal tetanus. Presently, the incidence in the United States is 0.01 per 100,000. Most patients who develop tetanus do not have a complete tetanus immunization or received inappropriate prophylaxis after a wound.
Unfortunately, tetanus continues to cause significant mortality in undeveloped nations. Worldwide, an estimated 1 million cases per year of tetanus with 200,000 deaths annually, with the majority of cases and death occurring in Southeast Asia and Africa. These areas have no resources for mass immunization programs, vaccines, or proper wound or traumatic injuries treatment. The World Health Organization fears that individuals affected by tetanus are dramatically low due to unreported cases. Many undeveloped nations do not even have reporting and surveillance systems in place.
C. tetani enter the body through a break in the skin or mucous membranes. Once within the body and in anaerobic conditions, the bacteria travel to the spinal cord and brainstem within the motor neuron. It then produces highly potent neurotoxin tetanospasmin. The toxin enters inhibitory interneurons and blocks neurotransmission at the synapses. There is then inactivation of inhibitory neurotransmission that normally modulates anterior horn cells and muscle contraction. Loss of inhibition of anterior horn cells will cause increased muscle tone and painful spasms. Loss of inhibition of autonomic neurons will cause widespread autonomic instability, mainly manifests as sweating, tachycardia, and hypertension. These effects are long-lasting, and recovery requires the growth of new nerve terminal.
In healthy tissues, C. tetani will not grow. The incubation period for tetanus ranges from three days to 21 days but usually starts about 8 days. Predisposing factors must be present with the absence of inadequate vaccination plus the following: penetrating or devitalizing type injuries, polymicrobial infections, missed foreign body in wounds or injuries, and any blood flow compromise. Approximately 25% with tetanus has no identifiable causes. Tetanus rarely occurs in patients who are timely and properly receive immunizations.
Tetanus vaccine is a type of artificial active immunity. This type of immunity produces antibodies when a dead or weakened version of C. tetani is inoculated. Thereby, when there is actual exposure, the immune system will recognize the antigen and will rapidly produce antibodies. Antibodies wane over time, so periodic vaccines will be needed to boost the production of antibodies.
A thorough medical history should be obtained. Focus on previous immunization or completion thereof and any previous complications of vaccination. Be wary of patients from other countries, especially coming from undeveloped nations. Ask about signs and symptoms of muscle spasms, stiffness, and pain. Ask if there is a history of wound or traumatic injuries, then ask about the mechanism of injury, timing, and any predisposing factors.
A thorough physical exam should be done. Look for muscle rigidity, tone, and spasm. If there is a wound, then note the size and depth of the wound, state of wound tissue, look for foreign body, and any sign of decreased blood flow.
Do not forget to ask and look for autonomic instability signs and symptoms such as profuse sweating, tachycardia, and labile hypertension or hypotension.
Tetanus should be suspected when there is a history of tetanus prone injury and inadequate immunization. Evaluation of a patient at risk for tetanus is based on a thorough history and physical examination. Tetanus is a clinical diagnosis. Laboratory tests are not helpful. No diagnostic studies are needed other than to rule out other mimics of tetanus such as dental abscess or meningitis. There are differences in the diagnosis of adults and neonates, described by the WHO (World Health Organization). For adults, WHO guidelines require clinical evidence of a history of an injury or wound and at least one of the following: painful muscular contractions, trismus, and risus sardonicus. In neonatal tetanus, an infant who in the first 2 days of life and able to cry and suck and then loses that ability in days 3 to 28 and develops spasms or becomes rigid, tetanus is suspected.
Trismus is caused by intense painful spasms of the masseter muscles with the inability to open the mouth. A clinical test with 100% specificity and 94% sensitivity is the "spatula test," which can be performed to help aid in the diagnosis of tetanus in the clinical setting. This is performed by touching the posterior wall of the oropharynx with a dull instrument, causing reflex jaw spam if tetanus is present.
Tetanus prophylaxis is determined by previous immunization and classifying low versus high-risk wound(s): unimmunized (less than 3 doses or unknown) versus immunized (greater than 3 doses), low risk (clean and minor) versus high risk (contaminated, puncture, avulsions, or resulting from missiles, crushing, burns, animal or human bites, or frostbite). In an unimmunized individual with low-risk wound, the tetanus vaccine is indicated; if high risk, then both vaccine and human tetanus immune globulin (HTIG) are also indicated. In immunized individuals with low-risk wounds, the tetanus vaccine is indicated only if the last dose was given more than 10 years ago. If high risk, then the vaccine is indicated moreif the last booster was more than 5 years ago. Prophylaxis should be administered as soon as possible following wound or traumatic injury and even upon delayed presentation due to the long and variable incubation period of tetanus. Of note, HTIG can be given up to 21 days for unvaccinated individuals if indicated. Tetanus toxin is irreversibly bound to tissues, therefore only unbound toxin is available for neutralization. The use of passive immunization such as HTIG to neutralize unbound toxin is associated with improved survival, and it is considered to be standard treatment. In undeveloped nations where HTIG is unavailable, anti-tetanus horse serum can be used but with great adverse effects. If HTIG is indicated and used, part of the dose needs to be injected around the wound or site of a traumatic injury.
All tetanus prophylaxis should be used in conjunction with timely cleaning and debridement of wounds. Patients should receive immediate surgical treatment if indicated. Tetanus-prone wounds may be left open to avoid anaerobic conditions.
In pregnancy, it is a category C vaccine and is indicated to give Tdap in 27 to 36 weeks and every pregnancy regardless of the last dose. If unvaccinated, then a series of three will be given 4 weeks apart.
In patients with HIV/AIDS, HTIG is indicated regardless of immunization status or wound classification.
There is no cure for tetanus. Treatment is supportive as best. Prevention is the best strategy by following immunization guidelines with a booster every 10 years and proper identification and prophylaxis of wound and traumatic injuries. Vaccinations do give life long immunity if such guidelines and recommendations are followed.
Common side effects are fever, redness, swelling, and pain at the injection site, which is usually the deltoid and thigh regions. Fever is more common in routine vaccinations when administered with concurrent vaccines. Anaphylaxis, urticaria, angioedema, and neurologic complications have been reported following tetanus vaccine administration but rare. Contraindications are an anaphylactic reaction to the previous dose and encephalopathy not attributed to other causes within 7 days of the previously given dose. Precautions should be considered for GBS within 6 weeks of previous dose, history of Arthus-type reaction, or underlying neurologic conditions.
Tetanus continues to cause significant mortality in the developing world. Approximately 2 out of every 10 individuals who develop the disease will not survive. Tetanus does not provide any immunity; those who survive should be actively immunized. Cephalic and neonatal tetanus have poor outcomes. Complete recovery may take months due to the requirement of new nerve terminal growth, which is usually 4 to 6 weeks.
Although rare in developed nations, complications arise from unvaccinated, missed booster vaccines, and improper treatment of wounds and traumatic injuries. Once tetanus is diagnosed, it is only supportive care and often too late with high morbidity and mortality.
Patient and parent education is a key factor in reducing vaccine-preventable diseases. Awareness of vaccination is low, and individuals depend on their healthcare providers in educating them on recommendations. This is especially true in the fight to close the widening gap in racial and ethnic disparities when it comes to vaccination coverage. Per the Community Preventive Services Task Force and the National Vaccine Advisory Committee, when health care providers interact with their patients in a clinical setting, a conversation should address the need for and recommendations pertaining to vaccines in general. Along with this conversation, patients should be offered appropriate vaccinations.
Preventing tetanus infection by tetanus prophylaxis is dependent on the intervention of interprofessional teams. Gathering of information may be performed by an interprofessional team that includes emergency medicine physicians, nurse practitioners, physician assistants, primary care providers, surgeons, along with nurses and pharmacists on the history of a patient and why they are presenting to the clinic, office or emergency department. This ensures that a patient who presents with risk factors for developing tetanus is administered prophylaxis in a timely manner, thus preventing the disease.
|||Rhinesmith E,Fu L, Tetanus Disease, Treatment, Management. Pediatrics in review. 2018 Aug; [PubMed PMID: 30068747]|
|||Havers FP,Moro PL,Hunter P,Hariri S,Bernstein H, Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR. Morbidity and mortality weekly report. 2020 Jan 24; [PubMed PMID: 31971933]|
|||McQuillan GM,Kruszon-Moran D,Deforest A,Chu SY,Wharton M, Serologic immunity to diphtheria and tetanus in the United States. Annals of internal medicine. 2002 May 7 [PubMed PMID: 11992301]|
|||Rossetto O,Montecucco C, Tables of Toxicity of Botulinum and Tetanus Neurotoxins. Toxins. 2019 Nov 22; [PubMed PMID: 31771110]|
|||Tetanus surveillance --- United States, 2001-2008. MMWR. Morbidity and mortality weekly report. 2011 Apr 1 [PubMed PMID: 21451446]|
|||Roper MH, Tetanus prophylaxis in the emergency department. Annals of emergency medicine. 2004 Mar; [PubMed PMID: 14985656]|
|||Miller T,Olivieri P,Singer E, The utility of Tdap in the Emergency Department. The American journal of emergency medicine. 2017 Sep; [PubMed PMID: 28363621]|
|||Ergonul O,Egeli D,Kahyaoglu B,Bahar M,Etienne M,Bleck T, An unexpected tetanus case. The Lancet. Infectious diseases. 2016 Jun [PubMed PMID: 27301930]|
|||Dong M,Masuyer G,Stenmark P, Botulinum and Tetanus Neurotoxins. Annual review of biochemistry. 2019 Jun 20; [PubMed PMID: 30388027]|
|||Pellizzari R,Rossetto O,Schiavo G,Montecucco C, Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical transactions of the Royal Society of London. Series B, Biological sciences. 1999 Feb 28; [PubMed PMID: 10212474]|
|||Tetanus vaccines: WHO position paper, February 2017 - Recommendations. Vaccine. 2018 Jun 14; [PubMed PMID: 28427847]|
|||Tetanus vaccines: WHO position paper – February 2017. Releve epidemiologique hebdomadaire. 2017 Feb 10; [PubMed PMID: 28185446]|
|||Walter EB,Klein NP,Wodi AP,Rountree W,Todd CA,Wiesner A,Duffy J,Marquez PL,Broder KR, Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. Pediatrics. 2020 Mar; [PubMed PMID: 32029684]|
|||Williams WW,Lu PJ,O'Halloran A,Bridges CB,Kim DK,Pilishvili T,Hales CM,Markowitz LE, Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. MMWR. Morbidity and mortality weekly report. 2015 Feb 6; [PubMed PMID: 25654611]|